Merus' Series B - II Round

Merus raised a round of funding on October 03, 2013.

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured …

Articles about Merus' Series B - II Round: